Pimobendan for Canine Myxomatous Mitral Valve Disease (MMVD): Evidence, Mechanism, and Use

Bottom line

• Pimobendan is an inodilator approved for canine congestive heart failure (CHF) secondary to myxomatous mitral valve disease (MMVD) and dilated cardiomyopathy (DCM); it combines calcium sensitization of cardiac troponin C with phosphodiesterase-3 (PDE3) inhibition, increasing myocardial contractility without proportionally raising oxygen demand while also producing arterial and venous vasodilation.¹
• In preclinical Stage B2 MMVD (echocardiographic cardiomegaly, no CHF signs), the multicenter EPIC RCT (360 dogs) showed pimobendan delayed the composite primary endpoint (onset of CHF, cardiac-related death, or euthanasia) from a median of 766 days to 1228 days — a hazard ratio of 0.64 (95% CI 0.47–0.87, P = .0038) — representing approximately 15 months of additional preclinical time.²
• In dogs with established CHF from MMVD, the QUEST study (260 dogs) showed pimobendan added to conventional therapy extended median time to sudden cardiac death, cardiac euthanasia, or treatment failure from 140 days (benazepril arm) to 267 days (pimobendan arm), hazard ratio 0.688 (95% CI 0.516–0.916, P = .0099).³
• The 2019 ACVIM consensus guidelines recommend pimobendan for Stage B2 MMVD (with qualifying echocardiographic and radiographic cardiomegaly thresholds) and for all stages of symptomatic heart failure (Stage C and D) caused by MMVD.⁴
• This is a clinician-facing evidence summary. It is not a dosing protocol; confirm regimen, monitoring and contraindications against current product labeling and a veterinary formulary.

Drug facts

• Class: Benzimidazole-pyridazinone inodilator (positive inotrope + vasodilator).¹
• Dual mechanism: (1) Calcium sensitization — pimobendan binds troponin C and increases myofilament calcium affinity, improving contractility without increasing intracellular calcium load; (2) PDE3 inhibition — inhibiting phosphodiesterase 3 raises cyclic AMP in cardiac and vascular smooth muscle, augmenting inotropy and producing vasodilation.¹
• Route/interval: Oral, typically given twice daily; defer the specific dose per kilogram to current product labeling and a veterinary formulary.²
• Indications discussed here: Canine MMVD (Stage B2 with qualifying cardiomegaly criteria, Stage C, Stage D) and preclinical DCM (see PROTECT study); approved for CHF secondary to MMVD and DCM.^1,4
• Active metabolite: O-desmethyl-pimobendan (ODMP) has more potent PDE3 inhibitory activity than the parent compound and is clinically relevant.¹

A specific patient on pimobendan?

Get an instant cited answer — no signup needed for your first question. Voyage Clinical Desk brings species-specific dose math, monitoring plans, and peer-reviewed evidence to the case in front of you.

Try Voyage Clinical Desk

What the evidence shows

Mechanism: why pimobendan is an inodilator, not a pure inotrope

Pimobendan belongs to the benzimidazole-pyridazinone class and works through two complementary pathways.¹ First, as a calcium sensitizer, it binds troponin C and increases the affinity of the contractile proteins for calcium, thereby improving stroke volume at any given intracellular calcium concentration — an advantage over traditional inotropes that raise intracellular calcium and oxygen demand proportionally.¹ Second, PDE3 inhibition by pimobendan and especially by its active metabolite ODMP elevates cyclic AMP in both cardiac myocytes and vascular smooth muscle, contributing positive inotropy and producing arterial and venous vasodilation.¹ The net effect is improved cardiac output with reduced cardiac loading — the pharmacodynamic basis for its role across disease stages.

Stage B2 MMVD: EPIC trial

The landmark evidence for preclinical MMVD comes from the EPIC study, a prospective randomized, placebo-controlled, blinded, multicenter trial in 360 client-owned dogs with MMVD and documented echocardiographic and radiographic cardiomegaly (left atrial-to-aortic ratio ≥1.6, normalized left ventricular internal diameter in diastole ≥1.7, and vertebral heart sum >10.5) who were not receiving other cardiovascular medications.² The primary outcome was time to a composite of CHF onset, cardiac-related death, or euthanasia.

Median time to the primary endpoint was 1228 days (95% CI: 856–not reached) in the pimobendan group versus 766 days (95% CI: 667–875) in the placebo group (P = .0038). The hazard ratio for pimobendan was 0.64 (95% CI: 0.47–0.87).² The benefit persisted after multivariable adjustment. Dogs in the pimobendan group also lived longer: median survival 1059 days versus 902 days in the placebo group (P = .012).² Adverse events were not significantly different between groups. The authors concluded that administration of pimobendan to dogs with MMVD and echocardiographic and radiographic evidence of cardiomegaly results in prolongation of the preclinical period, and that prolongation by approximately 15 months represents substantial clinical benefit.²

Stage C and D MMVD: QUEST study

For dogs already in CHF from MMVD, the QUEST study (260 dogs, 28 centers, Europe, Canada, Australia) randomized patients to pimobendan (0.4–0.6 mg/kg/d) or benazepril hydrochloride (0.25–1.0 mg/kg/d), both on a background of conventional therapy.³ The primary endpoint was a composite of cardiac death, cardiac euthanasia, or treatment failure. Median time to the primary endpoint was 267 days for pimobendan versus 140 days for benazepril (hazard ratio 0.688, 95% CI 0.516–0.916, P = .0099).³ The authors concluded that pimobendan plus conventional therapy prolongs time to sudden death, euthanasia for cardiac reasons, or treatment failure compared with benazepril plus conventional therapy in dogs with CHF caused by MMVD.³

ACVIM 2019 staging and pimobendan recommendations

The 2019 ACVIM consensus guidelines, issued by the Specialty of Cardiology consensus panel, updated the 2009 guidelines and codified pimobendan's role across disease stages.⁴ Stage B2 — asymptomatic dogs with hemodynamically significant mitral regurgitation causing left atrial and ventricular enlargement meeting clinical trial qualifying thresholds — is now an indication for pimobendan initiation, reflecting the EPIC data.⁴ Stage C (current or past CHF signs) and Stage D (refractory CHF) are indications where pimobendan is a central component of therapy. The guidelines note that management of MMVD before the onset of clinical signs of heart failure has changed substantially compared with the 2009 guidelines.⁴ The cardiomegaly criteria from EPIC (LA/Ao ≥1.6 and LVIDdN ≥1.7) inform the Stage B2 threshold used to identify patients who clearly benefit from treatment initiation.⁴

Pimobendan in DCM: PROTECT study

Although the primary focus of this article is MMVD, pimobendan's preclinical use extends to DCM in Doberman Pinschers. The PROTECT study (randomized, blinded, placebo-controlled, multicenter, 76 Dobermans) showed that pimobendan significantly prolonged median time to the primary endpoint (onset of CHF or sudden death): 718 days (IQR 441–1152) in the pimobendan group versus 441 days (IQR 151–641) in placebo (log-rank P = .0088), and also extended median survival time (P = .034).⁵ This demonstrates the inodilator's utility across the spectrum of canine cardiac disease, both valvular and myocardial.

How this fits clinical practice

Pimobendan occupies a central position in canine cardiac pharmacology across multiple disease stages. For MMVD, the weight of evidence — from mechanistic pharmacology through pivotal multicenter RCTs — supports a staged approach: initiate at Stage B2 when the ACVIM echocardiographic and radiographic cardiomegaly thresholds are met, continue through CHF (Stage C and D) as a backbone of therapy. For preclinical DCM in Doberman Pinschers, similar preclinical benefit has been demonstrated. The echocardiographic criteria for Stage B2 matter clinically: studies have shown that pimobendan can produce reverse remodeling (reduction in LVIDdN) and that some dogs may no longer meet echocardiographic Stage B2 criteria after treatment — these should not be reclassified as Stage B1 and should continue therapy. Do not infer specific milligram-per-kilogram doses from this summary; always confirm the exact regimen, interval, monitoring plan, and contraindications against current product labeling and a veterinary formulary before prescribing.

Voyage Clinical Desk

From clinical question to SOAP draft — cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.

Open Voyage Clinical Desk

References

1. Boyle KL, Leech E. 2012. A review of the pharmacology and clinical uses of pimobendan. J Vet Emerg Crit Care (San Antonio) 22(4):398-408. https://europepmc.org/article/MED/22928748 [via]
2. Boswood A, Häggström J, Gordon SG, et al. 2016. Effect of pimobendan in dogs with preclinical myxomatous mitral valve disease and cardiomegaly: the EPIC study — a randomized clinical trial. J Vet Intern Med 30(6):1765-1779. https://europepmc.org/article/MED/27678080
3. Häggström J, Boswood A, O'Grady M, et al. 2008. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study. J Vet Intern Med 22(5):1124-1135. https://europepmc.org/article/MED/18638016
4. Keene BW, Atkins CE, Bonagura JD, et al. 2019. ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. J Vet Intern Med 33(3):1127-1140. https://europepmc.org/article/MED/30974015 [via]
5. Summerfield NJ, Boswood A, O'Grady MR, et al. 2012. Efficacy of pimobendan in the prevention of congestive heart failure or sudden death in Doberman Pinschers with preclinical dilated cardiomyopathy (the PROTECT study). J Vet Intern Med 26(6):1337-1349. https://europepmc.org/article/MED/23078651

Changelog

• 2026-06-22: First published.